Ian A Critchley

Summary

Publications

  1. doi request reprint Review of ceftaroline fosamil microbiology: integrated FOCUS studies
    Ian A Critchley
    Cerexa, Inc, Oakland, CA 94612, USA
    J Antimicrob Chemother 66:iii45-51. 2011
  2. doi request reprint Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections
    Ian A Critchley
    Replidyne, Inc, Louisville, CO 80027, USA
    J Antimicrob Chemother 63:954-63. 2009
  3. pmc Mode of action and biochemical characterization of REP8839, a novel inhibitor of methionyl-tRNA synthetase
    Urs A Ochsner
    Replidyne, Inc, Louisville, Colorado 80027, USA
    Antimicrob Agents Chemother 49:4253-62. 2005
  4. pmc Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001
    Ian A Critchley
    Focus Technologies, Inc, Herndon, Virginia, USA
    Antimicrob Agents Chemother 47:1689-93. 2003
  5. doi request reprint Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model
    Urs A Ochsner
    Replidyne, Inc, Louisville, CO 80027, USA
    J Antimicrob Chemother 63:964-71. 2009
  6. pmc National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study
    Ian A Critchley
    Replidyne, Inc, 1450 Infinite Drive, Louisville, CO 80027, USA
    Antimicrob Agents Chemother 51:4382-9. 2007
  7. ncbi request reprint Phenotypic and genotypic analysis of levofloxacin-resistant clinical isolates of Streptococcus pneumoniae collected in 13 countries during 1999-2000
    Ian A Critchley
    Focus Technologies, Inc, 13665 Dulles Technology Drive, Herndon, VA 20171, USA
    Int J Antimicrob Agents 20:100-7. 2002
  8. pmc Determining Linezolid's baseline in vitro activity in Canada using gram-positive clinical isolates collected prior to its national release
    James A Karlowsky
    Focus Technologies, Inc, Herndon, Virginia 20171 4603, USA
    Antimicrob Agents Chemother 46:1989-92. 2002
  9. pmc Antibacterial activity of REP8839, a new antibiotic for topical use
    Ian A Critchley
    Replidyne, Inc, Louisville, CO 80027, USA
    Antimicrob Agents Chemother 49:4247-52. 2005
  10. doi request reprint Recent advances in the preclinical evaluation of the topical antibacterial agent REP8839
    Ian A Critchley
    Microbiology Research, Replidyne, Inc, 1450 Infinite Drive, Louisville, CO 80027, USA
    Curr Opin Chem Biol 12:409-17. 2008

Detail Information

Publications13

  1. doi request reprint Review of ceftaroline fosamil microbiology: integrated FOCUS studies
    Ian A Critchley
    Cerexa, Inc, Oakland, CA 94612, USA
    J Antimicrob Chemother 66:iii45-51. 2011
    ..pneumoniae, H. influenzae and methicillin-susceptible S. aureus were susceptible to ceftaroline, with MIC(90)s of 0.03, 0.03 and 0.25 mg/L, respectively, supporting its utility as a promising new agent for treatment of CAP...
  2. doi request reprint Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections
    Ian A Critchley
    Replidyne, Inc, Louisville, CO 80027, USA
    J Antimicrob Chemother 63:954-63. 2009
    ..The aim of this study was to characterize the antimicrobial profile of REP3123, a novel inhibitor of methionyl-tRNA synthetase (MetRS) in development for the treatment of Clostridium difficile infection...
  3. pmc Mode of action and biochemical characterization of REP8839, a novel inhibitor of methionyl-tRNA synthetase
    Urs A Ochsner
    Replidyne, Inc, Louisville, Colorado 80027, USA
    Antimicrob Agents Chemother 49:4253-62. 2005
    ..In conclusion, we demonstrate by biochemical, physiologic, and genetic mode-of-action studies that REP8839 exerts its antibacterial activity through specific inhibition of MetS, a novel target...
  4. pmc Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001
    Ian A Critchley
    Focus Technologies, Inc, Herndon, Virginia, USA
    Antimicrob Agents Chemother 47:1689-93. 2003
    ..This study may serve as a baseline to monitor future changes in the susceptibility of gram-positive species to daptomycin following its introduction into clinical use...
  5. doi request reprint Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model
    Urs A Ochsner
    Replidyne, Inc, Louisville, CO 80027, USA
    J Antimicrob Chemother 63:964-71. 2009
    ..This novel agent was investigated for its ability to block the production of toxins and spores, and was tested for efficacy in vivo in a hamster model...
  6. pmc National and regional assessment of antimicrobial resistance among community-acquired respiratory tract pathogens identified in a 2005-2006 U.S. Faropenem surveillance study
    Ian A Critchley
    Replidyne, Inc, 1450 Infinite Drive, Louisville, CO 80027, USA
    Antimicrob Agents Chemother 51:4382-9. 2007
    ..5 mug/ml for S. pneumoniae, 1 mug/ml for H. influenzae, and 0.5 mug/ml for M. catarrhalis, suggesting that faropenem shows promise as a treatment option for respiratory infections caused by contemporary resistant phenotypes...
  7. ncbi request reprint Phenotypic and genotypic analysis of levofloxacin-resistant clinical isolates of Streptococcus pneumoniae collected in 13 countries during 1999-2000
    Ian A Critchley
    Focus Technologies, Inc, 13665 Dulles Technology Drive, Herndon, VA 20171, USA
    Int J Antimicrob Agents 20:100-7. 2002
    ..Future studies to characterise resistant isolates by other molecular methods may ensure that the appropriate counter-measures can be taken to control the spread of resistant isolates...
  8. pmc Determining Linezolid's baseline in vitro activity in Canada using gram-positive clinical isolates collected prior to its national release
    James A Karlowsky
    Focus Technologies, Inc, Herndon, Virginia 20171 4603, USA
    Antimicrob Agents Chemother 46:1989-92. 2002
    ..Future studies will determine how linezolid clinical use in Canada affects its in vitro activity...
  9. pmc Antibacterial activity of REP8839, a new antibiotic for topical use
    Ian A Critchley
    Replidyne, Inc, Louisville, CO 80027, USA
    Antimicrob Agents Chemother 49:4247-52. 2005
    ..aureus highlights the need for a new topical antibiotic with the ability to inhibit high-level mupirocin-resistant strains and other emerging phenotypes, such as vancomycin-resistant and community-acquired methicillin-resistant isolates...
  10. doi request reprint Recent advances in the preclinical evaluation of the topical antibacterial agent REP8839
    Ian A Critchley
    Microbiology Research, Replidyne, Inc, 1450 Infinite Drive, Louisville, CO 80027, USA
    Curr Opin Chem Biol 12:409-17. 2008
    ..aureus and can be formulated at high concentrations to minimize the development of resistance. A formulation of REP8839 has demonstrated efficacy in a porcine partial thickness wound infection model against mupirocin-resistant S. aureus...
  11. doi request reprint Quinazolin-2-ylamino-quinazolin-4-ols as novel non-nucleoside inhibitors of bacterial DNA polymerase III
    Joseph Guiles
    Replidyne, Inc, 1450 Infinite Dr, Louisville, CO 80027, USA
    Bioorg Med Chem Lett 19:800-2. 2009
    ..The inhibition of chromosomal DNA replication results in bacterial cell death. The synthesis, structure-activity relationships and functional activity are described...
  12. doi request reprint Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity
    Donald Biek
    Cerexa, Inc, Oakland, CA 94612, USA
    J Antimicrob Chemother 65:iv9-16. 2010
    ..8% of all baseline cSSSI isolates from the microbiologically evaluable population were inhibited by ceftaroline at ≤ 2 mg/L. Ceftaroline fosamil is a promising broad-spectrum agent for the treatment of cSSSIs...
  13. ncbi request reprint Activity of cefditoren against beta-lactamase-positive and -negative Haemophilus influenzae and Moraxella catarrhalis
    James A Karlowsky
    Focus Technologies, Inc, 13665 Dulles Technology Drive, Herndon, Virginia 20171, USA
    Diagn Microbiol Infect Dis 42:53-8. 2002
    ..5 and 1 microg/mL inhibited 93.1 and 100% of M. catarrhalis isolates, respectively. We conclude that cefditoren is highly active in vitro against beta-lactamase-positive H. influenzae and M. catarrhalis...